Hendrik W. van Deventer

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

Robert Z. Orlowski, Peter M. Voorhees, Reynaldo Garcia et al. · Blood · 2004 · 319 citations

The Inflammasome Component Nlrp3 Impairs Antitumor Vaccine by Enhancing the Accumulation of Tumor-Associated Myeloid-Derived Suppressor Cells

Hendrik W. van Deventer, Joseph E. Burgents, Qing Wu et al. · Cancer Research · 2010 · 163 citations · Full text

Circulating Fibrocytes Prepare the Lung for Cancer Metastasis by Recruiting Ly-6C+ Monocytes Via CCL2

Hendrik W. van Deventer, Daniela Palmieri, Qing Wu et al. · The Journal of Immunology · 2013 · 89 citations · Full text

Inflammation, Ccl2 Expression, Fibrosis +15

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, Robert K. Stuart, Jonathan Webster et al. · Blood · 2019 · 69 citations

C-C Chemokine Receptor 5 on Pulmonary Fibrocytes Facilitates Migration and Promotes Metastasis via Matrix Metalloproteinase 9

Hendrik W. van Deventer, Qing Wu, Dan T. Bergstralh et al. · American Journal Of Pathology · 2008 · 60 citations · Full text

Matrix Metalloproteinase 9, Fibrosis, Inflammatory Lung Disease +9